Baxter International Inc. is facing significant business disruption following safety concerns related to its recently launched Novum LVP infusion device. In April 2025, media reports highlighted inaccurate infusion rates and underinfusion risks, prompting some hospital systems to remove the devices from service. Baxter subsequently issued a warning letter to customers and, on July 31, 2025, announced a voluntary and temporary pause on shipments and installations of the Novum LVP. The company's stock price dropped by over 22% following the announcement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baxter International Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1112121) on December 01, 2025, and is solely responsible for the information contained therein.
Comments